Quinapril
As of the edition of 20 October 2026, Quinapril is a small molecule: marketed, first approved in 1989 (FR); acts on ACE.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1991
- Kind
- Small molecule
- Brand name
- Accupril
- First approved
- 14 April 1989 (FR)
- Approvals on record
- 9 in 3 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 13, 1 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Immune system; Nervous system; Nutrition and metabolism; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ACE | Angiotensin-converting enzyme | P12821 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 4 | 7 | 5 | 0 | 1 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Originator and Lead sponsor of trials | 1991 to now |